Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 27, 2015 | March 03, 2015 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2015 · Filed March 03, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 108,972 |
Reported balance
After 2015-02-27 transaction · row 1
1 source rowRow 1 · 2015-02-27 · Tax withholding · Disposed 11,530 · Balance 108,972 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,963 |
Reported balance
Holding disclosure · report date 2015-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,963 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2015. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy self for son | 171 |
Reported balance
Holding disclosure · report date 2015-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 171 F2: The reporting person disclaims beneficial ownership of all securities held by his son. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2015.
F2: The reporting person disclaims beneficial ownership of all securities held by his son.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2015 Filed Mar 3, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,530 | $47.61 | $548,943.30 |
DisclosureSEC source: 0001179110-15-004024 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,972 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 165,292 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003321 · edgar.xml · derivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,292 Underlying: Common shares · 165,292 shares Expires 2025-02-19 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 55,098 on 2/20/16, 55,097 on 2/20/17, and 55,097 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003321 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,502 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 03, 2014 Filed Jun 5, 2014 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,956 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001179110-14-009848 · edgar.xml · derivative · entry 7 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,956 shares Expires 2014-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 03, 2014 Filed Jun 5, 2014 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,247 | $0.00 Strike: $31.43 | $0.00 |
DisclosureSEC source: 0001179110-14-009848 · edgar.xml · derivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 6,247 shares Expires 2014-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 03, 2014 Filed Jun 5, 2014 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 16,284 | $39.80 | $648,103.20 |
DisclosureSEC source: 0001179110-14-009848 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,050 Read SEC document |
| June 03, 2014 Filed Jun 5, 2014 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,956 | $32.16 | $384,455.94 |
DisclosureSEC source: 0001179110-14-009848 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2014 Filed Jun 5, 2014 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,247 | $31.43 | $196,315.10 |
DisclosureSEC source: 0001179110-14-009848 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2014 Filed Feb 24, 2015 22:34 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 16,289 | $39.80 | $648,302.20 |
DisclosureSEC source: 0001179110-15-003320 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,045 F1 · shares: This Form 4/A amends the number of shares delivered or withheld for payment of exercise price or tax liability. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 807 | $39.40 | $31,796.61 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,131 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,307 | $39.40 | $248,495.80 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,938 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 192 | $39.39 | $7,562.88 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,245 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,377 | $39.38 | $54,226.26 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,437 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,610 | $39.37 | $338,975.70 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,814 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,307 | $39.79 | $609,065.53 |
DisclosureSEC source: 0001179110-14-004294 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,424 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 154,953 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003631 · edgar.xml · derivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,953 Underlying: Common Shares · 154,953 shares Expires 2024-02-20 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 51,651 on 2/21/2015, 51,651 on 2/21/2016, and 51,651 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 25,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003631 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,731 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption(right to buy) · Derivative | 1,583 | $0.00 Strike: $35.03 | $0.00 |
DisclosureSEC source: 0001179110-14-003112 · edgar.xml · derivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,583 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon Shares without par value | 600 | $39.11 | $23,463.00 |
DisclosureSEC source: 0001179110-14-003112 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,421 Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon Shares without par value | 983 | $39.10 | $38,436.28 |
DisclosureSEC source: 0001179110-14-003112 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,021 Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon Shares without par value | 1,583 | $35.03 | $55,452.49 |
DisclosureSEC source: 0001179110-14-003112 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 21,972 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001179110-14-002504 · edgar.xml · derivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,972 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon Shares without par value | 11,572 | $36.96 | $427,701.12 |
DisclosureSEC source: 0001179110-14-002504 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,421 Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon Shares without par value | 10,400 | $36.95 | $384,280.00 |
DisclosureSEC source: 0001179110-14-002504 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,993 Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon Shares without par value | 21,972 | $32.16 | $706,529.43 |
DisclosureSEC source: 0001179110-14-002504 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2013 Filed Dec 20, 2013 23:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-018458 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,421 Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,414 | $34.26 | $459,563.64 |
DisclosureSEC source: 0001179110-13-003902 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,078 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 266 | $34.78 | $9,251.75 |
DisclosureSEC source: 0001179110-13-003141 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,492 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,800 | $34.78 | $97,389.60 |
DisclosureSEC source: 0001179110-13-003141 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,758 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,616 | $35.08 | $302,249.28 |
DisclosureSEC source: 0001179110-13-003141 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,558 Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003141 · edgar.xml · derivative · entry 7 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common shares · 165,000 shares Expires 2023-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 55,000 on 2/15/2014, 55,000 on 2/15/2015, and 55,000 on 2/15/2016. Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 31,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003141 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,174 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 07, 2012 Filed Feb 13, 2013 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 11,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-002648 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Anne Marie Landgraf Living Trust Disclosed balance after: 11,614 F2 · balance_after: Held in the Anne Marie Landgraf Living Trust. The reporting person and his spouse are co-trustees of the trust. The trust is revocable by his spouse. Read SEC document |
| November 07, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017666 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,474 Read SEC document |
| November 06, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017666 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,559 Read SEC document |
| October 26, 2012 Filed Dec 14, 2012 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 90 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-017666 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,759 Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 21,972 | $0.00 Strike: $66.92 | $0.00 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · derivative · entry 9 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,972 Underlying: Common shares · 21,972 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 11,956 | $0.00 Strike: $66.92 | $0.00 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · derivative · entry 8 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,956 Underlying: Common shares · 11,956 shares Expires 2014-08-02 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,057 | $0.00 Strike: $53.12 | $0.00 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · derivative · entry 7 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,057 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,920 | $0.00 Strike: $53.19 | $0.00 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · derivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 17,920 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,588 | $0.00 Strike: $53.19 | $0.00 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · derivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,588 shares Expires 2014-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 33,928 | $66.92 | $2,270,461.76 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,849 Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,057 | $53.12 | $374,867.84 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2012 Filed Sep 11, 2012 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,508 | $53.19 | $1,675,910.52 |
DisclosureSEC source: 0001179110-12-013903 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,247 | $0.00 Strike: $65.40 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 20 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 Underlying: Common shares · 6,247 shares Expires 2014-08-02 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,156 | $0.00 Strike: $51.21 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 19 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 7,156 shares Expires 2014-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,823 | $0.00 Strike: $55.57 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 18 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,823 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,835 | $0.00 Strike: $58.71 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 17 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 12,835 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,439 | $0.00 Strike: $54.30 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 16 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,439 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,935 | $0.00 Strike: $53.12 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 15 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,935 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.